http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
-
Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance
-
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2019 Investor Update Call
-
Ironwood Pharma (IRWD), Allergan (AGN) Settle LINZESS (linaclotide) Patent Litigation with Teva (TEVA)
-
Ironwood and Allergan Announce Settlement with Teva Resolving LINZESS® (linaclotide) Patent Litigation
-
Ironwood Pharma (IRWD), Allergan (AGN) Announce Settlement Resolving LINZESS Patent Litigation
-
Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation
-
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
-
Dermira Elects Halley E. Gilbert to its Board of Directors
-
Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference
-
Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance
-
Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting
-
Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call
-
Ironwood Pharma (IRWD), AstraZeneca (AZN) Collaborate in China on LINZESS
-
Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China
-
Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences
-
Ironwood (IRWD), Alnylam Pharma (ALNY) Enter U.S. GI Disease Education and Promotional Agreement for Alnylam's Givosiran in AHP
-
Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
-
Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
-
Ironwood Pharmaceuticals Reports Second Quarter 2019 Results
-
Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call
-
Ironwood Pharma (IRWD), Allergan (AGN) Announce Positive Topline Data from Phase IIIb Trial of LINZESS (linaclotide) in Adults with IBS-C
-
Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
-
Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston
-
Ironwood Pharma (IRWD), Allergen (AGN) Commence Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D
-
Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D
-
Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019
-
Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference
-
Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance
-
Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call
-
Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020
-
Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company
-
Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement
-
Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference
-
Ironwood Pharmaceuticals to Present at Cowen Health Care Conference
-
Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering
-
Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
-
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update
-
Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call
-
Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation
-
Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation
-
Ironwood Pharma (IRWD) Begins Phase 1 Trial of IW-6463
-
Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials
-
Ironwood Pharma (IRWD) Announces Approval of LINZESS in China for Treatment of Adults with IBS-C
-
Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C
-
Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer
-
Ironwood Pharma (IRWD) Confirms Mark Mallon as New CEO
-
Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation
-
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
-
Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation

